Stocks News

LAST PRICE
33.4700
TODAY'S CHANGE (%)
Trending Up1.1300 (3.4941%)

Bid / Lots
31.8700/ 1
Ask / Lots
35.7700/ 1
Open / Previous Close
32.2600 / 32.3400
Day Range
Low 32.2600
High 33.8600
52 Week Range
Low 25.7700
High 50.2300
Volume
404,183
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 20, 2024
- CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting, from 8:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  8:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: CGON
  
  CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
  
  Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in Progress Posters
Nov 13, 2024
- DJ CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 7:14AM ET on Wednesday Nov 13, 2024 by Dow Jones
  7:14AM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: CGON
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/CGON/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 13, 2024 07:14 ET (12:14 GMT)
Nov 12, 2024
- CG Oncology's Q3 Loss Narrows, from 9:01AM ET on Tuesday Nov 12, 2024 by MT Newswires
  9:01AM ET on Tuesday Nov 12, 2024 by MT Newswires
  Companies Mentioned: CGON
  09:01 AM EST, 11/12/2024 (MT Newswires) -- CG Oncology (CGON) reported a Q3 loss Tuesday of $0.30 per diluted share, narrower than a loss of $4 a year earlier. Analysts polled by Capital IQ expected a loss of $0.38. As expected, no revenue for the q...
- Press Release: CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: CGON
- CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
  Companies Mentioned: CGON
  
  CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
  
  - Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in BCG-Unresponsive NMIBC Accepted at the Society of Urologic Oncology (SUO) 25th Annual Meeting -

Nov 20, 2024
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of MARX, BRKH, MNTX and LPBH, from 6:06PM ET on Wednesday Nov 20, 2024 by Dow Jones
  6:06PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: MNTX, LBPH, BRKH, MARX
Nov 18, 2024
- Citigroup Initiates Akero Therapeutics at Buy With $65 Price Target, from 8:20AM ET on Monday Nov 18, 2024 by MT Newswires
  8:20AM ET on Monday Nov 18, 2024 by MT Newswires
  Companies Mentioned: AKRO
- DJ Akero Therapeutics Initiated at Buy by Citigroup, from 7:51AM ET on Monday Nov 18, 2024 by Dow Jones
  7:51AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: AKRO
- DJ Akero Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 7:42AM ET on Monday Nov 18, 2024 by Dow Jones
  7:42AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: AKRO
Nov 15, 2024
- Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting(R) 2024, from 11:00AM ET on Friday Nov 15, 2024 by Dow Jones
  11:00AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: AKRO
Nov 14, 2024
- Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: SLNO
Nov 13, 2024
- Akero Therapeutics to Present at the Jefferies London Healthcare Conference, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: AKRO
- Attention Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf, from 1:02PM ET on Wednesday Nov 13, 2024 by Dow Jones
  1:02PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: AKRO
- Attention Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf, from 1:01PM ET on Wednesday Nov 13, 2024 by Newsfile
  1:01PM ET on Wednesday Nov 13, 2024 by Newsfile
  Companies Mentioned: AKRO
Nov 12, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders, from 1:20PM ET on Tuesday Nov 12, 2024 by PR Newswire
  1:20PM ET on Tuesday Nov 12, 2024 by PR Newswire
  Companies Mentioned: ZUO, B, LBPH

CG Oncology Inc
NASDAQ:CGONUnited States

Search Criteria

Nov 20, 2024

CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting, from 8:00AM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 13, 2024

DJ CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co., from 7:14AM ET on Wednesday Nov 13, 2024 by Dow Jones

Nov 12, 2024

CG Oncology's Q3 Loss Narrows, from 9:01AM ET on Tuesday Nov 12, 2024 by MT Newswires

Press Release: CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates, from 8:00AM ET on Tuesday Nov 12, 2024 by Dow Jones

Peers Headlines

Nov 20, 2024

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of MARX, BRKH, MNTX and LPBH, from 6:06PM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 18, 2024

Citigroup Initiates Akero Therapeutics at Buy With $65 Price Target, from 8:20AM ET on Monday Nov 18, 2024 by MT Newswires

DJ Akero Therapeutics Initiated at Buy by Citigroup, from 7:51AM ET on Monday Nov 18, 2024 by Dow Jones

DJ Akero Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co., from 7:42AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 15, 2024

Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting(R) 2024, from 11:00AM ET on Friday Nov 15, 2024 by Dow Jones

Nov 14, 2024

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones

Attention Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf, from 1:02PM ET on Wednesday Nov 13, 2024 by Dow Jones

Attention Akero Therapeutics, Inc. (AKRO) Shareholders: Grabar Law Office Is Investigating Claims on Your Behalf, from 1:01PM ET on Wednesday Nov 13, 2024 by Newsfile

Nov 12, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of Shareholders, from 1:20PM ET on Tuesday Nov 12, 2024 by PR Newswire